No black box warning on record for Glydo- Lidocaine Hydrochloride Jelly

As of the latest FDA labeling reviewed, Glydo- Lidocaine Hydrochloride Jelly (GLYDO- LIDOCAINE HYDROCHLORIDE JELLY) does not carry a black box warning. Standard warnings and precautions still apply — see the full Glydo- Lidocaine Hydrochloride Jelly medicine page for the complete safety profile.

Other warnings & precautions

EXCESSIVE DOSAGE, OR SHORT INTERVALS BETWEEN DOSES, CAN RESULT IN HIGH PLASMA LEVELS AND SERIOUS ADVERSE EFFECTS. PATIENTS SHOULD BE INSTRUCTED TO STRICTLY ADHERE TO THE RECOMMENDED DOSAGE AND ADMINISTRATION GUIDELINES AS SET FORTH IN THIS PACKAGE INSERT. THE MANAGEMENT OF SERIOUS ADVERSE REACTIONS MAY REQUIRE THE USE OF RESUSCITATIVE EQUIPMENT, OXYGEN, AND OTHER RESUSCITATIVE DRUGS. GLYDO 2% Jell

No black box warning on record for Glydo- Lidocaine Hydrochloride Jelly

Other warnings & precautions

EXCESSIVE DOSAGE, OR SHORT INTERVALS BETWEEN DOSES, CAN RESULT IN HIGH PLASMA LEVELS AND SERIOUS ADVERSE EFFECTS. PATIENTS SHOULD BE INSTRUCTED TO STRICTLY ADHERE TO THE RECOMMENDED DOSAGE AND ADMINISTRATION GUIDELINES AS SET FORTH IN THIS PACKAGE INSERT. THE MANAGEMENT OF SERIOUS ADVERSE REACTIONS MAY REQUIRE THE USE OF RESUSCITATIVE EQUIPMENT, OXYGEN, AND OTHER RESUSCITATIVE DRUGS. GLYDO 2% Jell

Glydo- Lidocaine Hydrochloride Jelly Black Box Warning

No black box warning on record for Glydo- Lidocaine Hydrochloride Jelly

Other warnings & precautions

Glydo- Lidocaine Hydrochloride Jelly Black Box Warning

No black box warning on record for Glydo- Lidocaine Hydrochloride Jelly

Other warnings & precautions